Nivolumab belongs to the standard therapy in the second-line setting of metastatic renal cell carcinoma (mRCC). Although deep and long-lasting responses are seen in some patients, the majority of patients will further progress. PD-L1 is still under critical evaluation as a predictive biomarker. Thus, more accurate biomarkers are clearly warranted. Here, we investigated for the first time the predictive role of IDO-1, a negative immune-regulatory molecule, on clear cell RCC tissues of 15 patients undergoing nivolumab therapy. IDO-1 and other immune inhibitory molecules (PD-L1, PD-L2, FOXP3) as well as immune cell subsets (CD3, CD4 and CD8) were measured on formalin-fixed, paraffin-embedded sections of RCC specimens by immunohistochemistry.
vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKI) have revolutionized the daily treatment arsenal for more than 10 years now. 4, 5 However, complete responses are rarely seen (less than 1%) and, unfortunately, the majority of patients with initial response will experience disease progression 4, 6 due to adaptive or intrinsic resistance mechanisms as described in various preclinical models. 7, 8 Thus, potential predictive biomarkers are urgently needed to identify patients who will benefit most from certain antiangiogenic agents, but only a few clinical trials have investigated a comprehensive biomarker panel. 9 Presently, the field of immuno-oncology is dramatically changing the landscape of malignant diseases and immunotherapy has become a mainstay of cancer therapy. 10 Of those, immune checkpoint inhibitors, including PD-(L)1 and CTLA-4 blockers, yielded the most promising approach for activating therapeutic antitumor immunity so far. 11 In the Checkmate 025 phase III trial, for example, the anti-PD1
antibody nivolumab showed a prolongation of the overall survival (OS) for approximately 5 months compared to everolimus in patients with previously treated advanced RCC (25.0 vs 19.6 months, HR 0.73). The objective response rate (ORR) was also significantly higher in patients receiving nivolumab than everolimus (25% vs 5%, P < .001). 12 Despite these very encouraging data, most patients will not benefit from those therapies and PD-L1 expression at present is not a clear-cut exclusionary predictive biomarker as some patients with low PD-L1 expression also demonstrated robust responses. 13, 14 In various cancer entities, such as melanoma or urothelial carcinoma, expression of immune inhibitory molecules, such as PD-L1, IDO-1, FOXP3, TIM3 and LAG3, has been positively linked with a CD8 + T cell tumor microenvironment, reflecting negative feedback pathways that limit ongoing T cell activation. 15, 16 This fact means that upregulation of these immunosuppressive pathways is intrinsically induced by the immune system itself as a component of adaptive immune resistance rather than being an oncogenic driver of the tumor, resulting in an IFNc-mediated and inflammation-driven expression of immunosuppressive molecules. 11, 13, 15, 17 Thus, a better understanding of the dynamic interactions between both the tumor microenvironment and the host immune system is necessary for the development of more efficient and targeted biomarkers in this field. 13 Several in vivo and in vitro studies as well as clinical trials indicate that targeting and blocking more than one negative immune-regulatory mechanism may mediate better therapeutic effects by reducing the suppressive activity of T regulatory cells (Treg) and restoring the activity of effector T cells. 15, 18 Indoleamine 2,3-dioxygenase 1 (IDO-1) belongs to those negative immune-regulatory molecules that catalyzes tryptophan to kynurenine, which ends in the differentiation of na€ ıve T cells into an expansion, activation and recruitment of Tregs and myeloid-derived suppressor cells (MDSC) that further suppress anti-tumor T cells. 19, 20 In advanced RCC, the therapeutic efficacy, safety and tolerability of the combination of IDO-1 inhibitors (epacadostat) with checkpoint inhibitors (pembrolizumab) has been tested in a phase I/II study (ECHO-202/KEYNOTE-037) with promising preliminary results (NCT02178722) presented at the 2017 ASCO annual meeting.
The aim of the present pilot study was to investigate and to define, for the first time, the role of IDO-1 expression as a novel tar- immune-associated adverse events, no worsening of patient condition) and initial radiographic disease progression at 12 weeks continued therapy (treatment beyond progression) as already described previously, 21 with a short-term imaging 6 weeks later (after cycle 10 of nivolumab) to define definitive progressive disease.
Response to nivolumab was defined as complete response, partial response or stable disease from the time of immunotherapy start to objectively documented disease progression or subsequent therapy, whichever occurred first. The Netherlands).
| Tumor samples and regions
Staining was performed using an automated immunostainer (BenchMark ULTRA, Ventana Medical Systems, Tucson, USA), as already described in a previous IHC work by our study group. 22 In brief, formalin fixed, paraffin-embedded tissue sections were cut at PD-L1 and PD-L2 were assessed in tumor cells, immune cells and vessels as expression of these markers has been described in all 3 compartments. In all 3 compartments expression was scored semiquantitatively as 0 = negative, 1 = <1%, 2 = <5% and 3 = >5%.
IDO-1 expression was also assessed in tumor cells, in immune cells
as well as in vessels, and was scored as 0 = negative, 1 = 1%-10%, 2 = 10%-20% and 3 = >20% positivity, as described by Trott et al. 23 Representative stains for IDO-1 scoring are shown in Figure 1 . All counts were carried out by 2 independent observers (AB and BZ) using an Olympus BX50 microscope (409 magnification). Each investigator repeated all counts twice and the average of the repeated counts was used for statistical analyses.
| Statistical analysis
Descriptive statistics (absolute and relative frequencies for qualitative data; mean, SD and range for quantitative data) are given for T 
| RESULTS
Fifteen (10 men and 5 women) mRCC patients with a mean (AESD, median, range) age of 65.4 (AE9.9, 68, 50-79) years were included in this pilot study. Baseline and histopathological characteristics of primary RCC specimens stratified by immunotherapy response are shown in Table 1 . During a mean follow-up of 10.6 months, therapeutic response to nivolumab was noticed in 6 (40%) of 15 patients, whereas 9 (60%) patients confirmed disease progression and switched to 3rd line therapy using cabozantinib.
IDO-1 expression was totally absent in tumor cells and was only
present in a few macrophages, while the majority of the immune cells remained negative. In contrast, IDO-1 (≥1%) was expressed primarily in the endothelial cells of 13 (86.7%) RCC specimens.
Concerning therapeutic response to immunotherapy, all responders showed IDO-1 overexpression (score 3, >20%), while 66.7%
(n = 6) of non-responders confirmed a low IDO-1 expression (score 0-1, 0%-10%; P = .028), respectively. These results are in line with the fact that those patients with high IDO-1 expression (>10%) had a significantly longer PFS during immunotherapy compared to those patients with low IDO-1 expression (median: not estimated (NE) vs 3.5 months, P = .01 by log-rank test). Nevertheless, no significant differences were noticed concerning OS (P = .92 by log-rank test; Figure 2 ).
As a next step, we examined for correlation between immuneinhibitory molecules and the T cell-inflamed phenotype. A positive correlation was observed between IDO-1 expression and CD8 + T cell infiltration (r s = .691, P = .006), resulting in an inverse correlation between IDO-1 and CD4/CD8 ratio (r s = À.707, P = .004). In contrast, no significant correlation was noticed between the expression of IDO-1 and CD4 + T cell infiltration, Figure 3 . In contrast to CD4, significant differences in mean expression levels of immune cell subsets and immune-inhibitory molecules based on immunotherapy response were confirmed only for CD8 + T cells (mean value, responders vs non-responders: 119.5 vs 53.5; P = .002) and CD4/CD8 ratio (responders vs non-responders: 1.9 vs 4.4; P < .001) ( Figure 3 and Table 1 ).
PD-L1 negative tumor cells were seen in 13 (86.7%) patients, P-values by log-rank test; *P < .05; **P < .01; ***P < .001
pathways, higher CD8 + T cell infiltrates, with PD-L1 and IDO-1 overexpression was associated with a higher score of response signature to pembrolizumab in HPV-negative oral squamous cell carcinoma. 29 In addition, IDO-1 overexpression has been noticed in pretreatment melanomas from responders to PD-L1 inhibition. 30 In this study, we Approximately two years ago, nivolumab has been introduced as the first single agent and is until now the only FDA-and
Correlation analysis between IDO score and CD4 (A), CD8 (C) and CD4/ CD8 ratio (E) and scatter dot plots showing total expression levels of CD4 + T cells, CD8 + T cells and CD4/CD8 ratio depending on therapeutic response to immunotherapy (B, D, F). r s = Spearman's rank correlation coefficient; data represent median with interquartile range (*P < .05; **P < .01; ***P < .001); Mann-Whithney U test EMA-approved checkpoint inhibitor in the second-line treatment of advanced RCC according to the Checkmate 025 study, 12 demonstrating an OS and ORR improvement across multiple subgroups. 38 Although these data are very exciting, the ORR was maximally 32%, respectively. 38 In addition to the use of checkpoint inhibitors for monotherapy, there is now much focus on combining checkpoint inhibitors with other immunotherapies (ipilimumab plus nivolumab; Checkmate 016 39 and Checkmate 214 study; NCT02231749), 40 or with anti-angiogenic targeted thera- pathways that limit ongoing T cell activation (by activating T regulatory cells and blocking the ongoing activity of effector T cells). Thus, upregulation of immunosuppressive pathways is more intrinsically driven by the immune system itself rather than by cancer cells. 11, 13, [15] [16] [17] This fact suggests the hypothesis that blocking more than 1 immunosuppressive molecule by combining PD-1/PD-L1 inhibitors with IDO-1 inhibitors may improve the therapeutic response to immunotherapy
